DAX+0,07 % EUR/USD+0,11 % Gold-0,20 % Öl (Brent)+0,10 %

Quidel Corporation - (QDEL) Watchlist Pflicht - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

Die Aktie hat nicht schlecht Performt in den letzten Monaten und hat noch aufholpotential zum direkten Konkurenten.

Die Story könnte sicherlich weiter gehen.

Quidel Announces Third Quarter Financial Results; Total Revenues up 47%; Worldwide Product Sales up 58%



SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2005--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced financial results for the three and nine months ended September 30, 2005.

Third Quarter Financial Results

For the third quarter of 2005, total revenues rose 47% to $20.0 million led by 58% growth in product sales, as compared with total revenues of $13.6 million for the third quarter of 2004. Domestic product sales rose 35% for the third quarter of 2005 with a 39% increase in product sales across the Company`s core product lines, as compared with the third quarter of 2004. International product sales increased 130% for the third quarter of 2005 as compared with the third quarter of 2004, primarily due to initial shipments of influenza tests to the Company`s Japanese distributor.

Further comparing the third quarter of 2005 with the third quarter of 2004, gross margin improved to 53% from 46% due to higher sales and a more favorable product mix. Operating expenses declined to $9.4 million in the third quarter of 2005 from $11.5 million for the same period last year, primarily resulting from a decline in legal fees due to the previously-disclosed patent litigation settlement in April 2005, somewhat offset by planned increases in research and development and sales and marketing expenses associated with the Company`s QVB(TM) (Quidel Value Build) programs. Net earnings for the third quarter of 2005 were $0.7 million, or $0.02 per diluted share, as compared with a net loss of $3.6 million, or $0.12 per share, for the third quarter of 2004.
[posting]19.055.735 von Macros am 28.11.05 21:10:13[/posting]Bird Flu Names Advance on New Reports


Shares of companies linked to bird flu fears are generally higher after Nigeria reported a spread in the disease, Niger became the third African nation to report the virus. France initiated a vaccination program for geese and ducks today. China culled 22.5 million birds last year, but reported 2 new human cases over the weekend. China`s agricultural minister warned of a possible massive outbreak (VOA). Gainers range from Biocryst Pharma (BCRX +7%) to Emergency Filtration Products (otcbb: EMFP +15%) and Generex Biotech (GNBT +13%). Generex announced it would present a vaccine designed to protect against the potentially pandemic avian influenza virus this week.
Hier nochmal die Zahlen fürs 4te Quartal.

Quidel Announces Strong Fourth Quarter Results; Reports Earnings from Continuing Operations of $0.28 Per Share



SAN DIEGO--(BUSINESS WIRE)--Feb. 15, 2006--Quidel Corporation (NASDAQ:QDEL), a leader in point-of-care rapid diagnostic tests, today announced unaudited financial results for its fourth quarter and year ended December 31, 2005.

Fourth Quarter Financial Results

For the fourth quarter of 2005, total revenues rose 9% to $34.8 million, compared with total revenues of $31.9 million for the fourth quarter of 2004. Worldwide product sales growth of 8% for the fourth quarter of 2005 was led by Strep A with a 17% increase, pregnancy with an 11% increase and influenza with a 10% increase over prior year. International product sales increased 16% compared with the fourth quarter of 2004, due to increased demand for the Company`s influenza tests and bone health products.

Gross margin for the 2005 fourth quarter increased to 62% from 59% in the fourth quarter of 2004, primarily due to higher product sales, a more favorable geographic and product mix and a price increase on the majority of the Company`s products. Operating expenses for the fourth quarter of 2005 were $11.9 million, compared with $10.7 million for the fourth quarter of 2004. The increase in operating expenses relates primarily to planned increases in research and development, clinical trials, and sales and marketing expenses associated with the Company`s QVB(TM) (Quidel Value Build) programs.

For the fourth quarter of 2005, earnings from continuing operations were $9.8 million, or $0.28 per diluted share, compared with earnings from continuing operations of $6.0 million, or $0.19 per diluted share, for the fourth quarter of 2004. Loss on discontinued operations, net of tax, for the fourth quarter of 2005 was $0.2 million, or $0.00 per share, compared with a loss of $6.7 million, or $0.21 per share, for the fourth quarter of 2004. Net earnings for the fourth quarter of 2005 were $9.6 million, or $0.28 per diluted share, compared with a net loss of $0.6 million, or $0.02 per diluted share, for the fourth quarter of 2004.

Liquidity

Cash and cash equivalents as of December 31, 2005 were $34.9 million, compared with $36.3 million as of December 31, 2004. The year-over-year decrease in cash includes the one-time $17 million payment made as part of the previously-disclosed patent litigation settlement in April 2005.

2005 Full Year Financial Results

Total revenues for the year ended December 31, 2005 were $92.3 million, up 17% compared with total revenues of $78.7 million in 2004. Strong sales growth in all core product lines included full-year sales of influenza tests up 32%, pregnancy tests up 19%, and Strep A tests up 19%. Significant percentage growth was also recorded in mononucleosis and bone health products compared with 2004.

Gross margin for 2005 was 58%, compared with 54% in 2004, primarily reflecting higher product sales, a more favorable geographic and product mix, and a price increase on the majority of the Company`s products. Excluding the $17 million expense paid under the terms of the patent litigation settlement in the first quarter of 2005, operating expenses for 2005 were $43.5 million, compared with $41.6 million for 2004, primarily as a result of higher research and development costs associated with work on new technologies and increased market research, clinical trials, promotion and advertising costs for key products and development of brand value which were partially offset by lower legal fees for 2005 due to the previously-disclosed patent litigation settlement. The net loss for 2005 was $9.3 million, or $0.28 per diluted share, compared with a net loss for 2004 of $6.3 million, or $0.20 per diluted share, in 2004.


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.